Page last updated: 2024-12-06

vinconate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vinconate: synthetic hexa-hydrocanthane alkaloid; RN given refers to (+ -)-isomer; RN for cpd without isomeric designation not avai lable 8/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68896
CHEMBL ID2107714
SCHEMBL ID195244
MeSH IDM0116179

Synonyms (38)

Synonym
vinconate
vinconate [inn]
70704-03-9
vincantemat
einecs 274-789-7
vinconato [inn-spanish]
unii-807mp0mj61
vinconatum [inn-latin]
(+-)-methyl 3-ethyl-2,3,3a,4-tetrahydro-1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylate
1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylic acid, 3-ethyl-2,3,3a,4-tetrahydro-, methyl ester, (+-)-
(+-)-methyl 4-ethyl-3a,4,5,6-tetrahydro-3h-indolo(3.2.1-de)(1,5)naphthyridin-1-carboxylat
807mp0mj61 ,
vinconato
vinconatum
CHEMBL2107714
chanodesethylapovincamine
vincantenate
79087-56-2
1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylic acid, 2,3,3a,4-tetrahydro-3-ethyl-, methyl ester
vinconate [mi]
SCHEMBL195244
889s74l2kz ,
vinconate, (-)-
1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylic acid, 3-ethyl-2,3,3a,4-tetrahydro-, methyl ester, (+)-
vinconate, (+)-
unii-889s74l2kz
767257-65-8
1h-indolo(3,2,1-de)(1,5)naphthyridine-6-carboxylic acid, 3-ethyl-2,3,3a,4-tetrahydro-, methyl ester, (-)-
unii-usr9x88xyu
753420-20-1
usr9x88xyu ,
HY-U00316
CS-7317
Q7932298
methyl 6-ethyl-1,6-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-2,9(16),10,12,14-pentaene-2-carboxylate
chanodesethylapovincmine
DTXSID40867937
AKOS040740958

Research Excerpts

Actions

ExcerptReferenceRelevance
"The vinconate-induced increase in dialysate dopamine concentrations was significantly reduced by scopolamine (1 microM) and N0434 (1 microM), respectively."( Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies.
Iino, T; Katsura, M; Kuriyama, K, 1996
)
1.18

Treatment

Vinconate (10 mg/kg) treatment alleviated the decrease in correct choices and the increase in total errors induced by MS lesion. Treatment with vinconates before cerebral ischemia significantly suppressed neuronal cell loss in the hippocampal CA1 region.

ExcerptReferenceRelevance
"Vinconate treatment showed a tendency to reverse the decreases of serotonin in the fronto-parietal cortex and hippocampus and dopamine in the striatum."( Effects of vinconate on maze performance deficit induced by monoaminergic dysfunction in rats.
Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T, 1994
)
1.4
"Vinconate (10 mg/kg) treatment alleviated the decrease in correct choices and the increase in total errors induced by MS lesion."( Effects of vinconate on spatial learning impairments induced by medial septal lesion in rats.
Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T, 1992
)
1.39
"Treatment with vinconate (50 and 200 mg/kg i.p.) before cerebral ischemia significantly suppressed neuronal cell loss in the hippocampal CA1 region and the decrease in the content of neuroactive amino acids in the hippocampus."( Protective effect of vinconate on ischemia-induced neuronal damage in the rat hippocampus.
Iino, T; Katsura, M; Kuriyama, K, 1992
)
0.94
"Pretreatment with vinconate significantly reduced histopathological neuronal damage to the hippocampal CA1 sector following two 2-min ischemic insults."( Comparative protective effects of vinconate, baclofen, and pentobarbital against neuronal damage following repeated brief cerebral ischemia in the gerbil brain.
Araki, T; Kato, H; Kogure, K, 1991
)
0.88

Dosage Studied

ExcerptRelevanceReference
" All of the drugs, with the exception of vinconate, exhibited a monotonic dose-response curve and caused 100% survival at some dose."( Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice.
King, GA, 1987
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (19.35)18.7374
1990's24 (77.42)18.2507
2000's1 (3.23)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.17 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.13%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]